Age-associated blood methylation near NMDA receptor genes in a post-COVID cohort
In a cross-sectional re-analysis of whole blood from 94 people sampled six months after COVID-19, age-associated methylation signals clustered near glutamatergic/NMDA genes; without a COVID-negative group or symptom data, the authors call this hypothesis-generating. [1]
Automatic summary · not editorially reviewed
The key findings
The re-analysis was cross-sectional, with 94 samples in the age models and no COVID-19-negative comparator in the analysed model. [1]
GRIN1 and GRIN2C had high integrated evidence scores and showed age-associated hypermethylation. [1]
The authors say the analysis cannot determine whether the signals are COVID-19-specific, reflect accelerated biological ageing, or relate to cognitive symptoms. [1]
The source at a glance
- Study type / format
- Cross-sectional re-analysis of a whole-blood methylation dataset (abstract)
- Population / context
- People sampled six months after COVID-19 infection in a whole-blood methylation dataset (94 samples in the age models).
- Summary based on
- Study abstract
- Original publication
- July 18, 2026
Cross-sectional post-COVID blood methylation re-analysis
The authors re-analysed GSE247869, a whole-blood methylation dataset from people sampled six months after COVID-19 infection. The design was cross-sectional, with 94 samples in the age models and no COVID-19-negative comparator in the analysed model. Methylation was modelled at each measured site with age and sex as predictors, and results were corrected for multiple testing. The stated aim was to characterise age-associated methylation in this cohort, not to establish a COVID-19-specific signature or biological age acceleration.
Supporting source [1]
Glutamatergic gene signals among age-associated sites
The analysis identified 3,467 age-associated methylation sites at the reported false discovery rate, including sites near ELOVL2, FHL2, TRIM59, EDARADD, ASPA and PDE4C. The strongest exploratory signal was enrichment of glutamatergic/NMDA genes, including GRIN1, GRIN2C, GRIN2D, GRM1, GRM5 and SLC17A7. GRIN1 and GRIN2C had high integrated evidence scores and showed age-associated hypermethylation. The prioritised genes mapped interpretively to glutamatergic synapse, calcium signalling and cAMP signalling pathways, but these complete pathways were not tested as formal enrichment categories.
Supporting source [1]
No COVID-specific or cognitive conclusions possible
The authors state that the analysis cannot determine whether these signals are specific to COVID-19 infection, reflect accelerated biological ageing, or relate to cognitive symptoms, because no COVID-19-negative comparator or symptom-level cognitive phenotyping was included. The glutamatergic finding is described as hypothesis-generating, particularly because the curated gene set was small and no independent replication cohort was analysed. The authors call for longitudinal and case-control studies linking GRIN1/GRIN2C methylation with cognitive and inflammatory phenotyping, and say any pathway evaluation, including hypotheses related to the Cheung Glutamatergic Regimen, would require independent validation and careful safety evaluation.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Single cross-sectional post-COVID cohort, no COVID-19-negative comparator, no symptom-level cognitive phenotyping, small curated gene set, no independent replication, and pathway mapping was interpretive rather than formally tested.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.